Previous close | 0.0700 |
Open | 0.0500 |
Bid | 0.0000 |
Ask | 0.0500 |
Strike | 110.00 |
Expiry date | 2024-10-18 |
Day's range | 0.0500 - 0.0500 |
Contract range | N/A |
Volume | |
Open interest | 81 |
Cardinal Health and T2 Biosystems announce an agreement selecting the former to sell direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens.
Here is how Boston Scientific (BSX) and Arcellx, Inc. (ACLX) have performed compared to their sector so far this year.
DGX's strength in Advanced Diagnostics and robust base business volumes are encouraging.